BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 2018;17:153-78. [PMID: 29506920 DOI: 10.1016/j.jcf.2018.02.006] [Cited by in Crossref: 229] [Cited by in F6Publishing: 175] [Article Influence: 57.3] [Reference Citation Analysis]
Number Citing Articles
1 Zybert K, Wozniacki L, Tomaszewska‐sobczyńska A, Wertheim‐tysarowska K, Czerska K, Ołtarzewski M, Sands D. Clinical characteristics of rare CFTR mutations causing cystic fibrosis in Polish population. Pediatr Pulmonol 2020;55:2097-107. [DOI: 10.1002/ppul.24823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dolce D, Neri S, Grisotto L, Campana S, Ravenni N, Miselli F, Camera E, Zavataro L, Braggion C, Fiscarelli EV, Lucidi V, Cariani L, Girelli D, Faelli N, Colombo C, Lucanto C, Lombardo M, Magazzù G, Tosco A, Raia V, Manara S, Pasolli E, Armanini F, Segata N, Biggeri A, Taccetti G. Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study. PLoS One 2019;14:e0213497. [PMID: 30901344 DOI: 10.1371/journal.pone.0213497] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
3 Sasaki E, Kostocenko M, Lang N, Clark T, Rogers M, Muldowney R, Walsh O, O'Grady L, Edge G, Ward A, Linnane B, Borovickova I, Barton DE, Lynch SA. National Newborn Screening for cystic fibrosis in the Republic of Ireland: genetic data from the first 6.5 years. Eur J Hum Genet 2020;28:1669-74. [PMID: 32483343 DOI: 10.1038/s41431-020-0661-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Skov M, Hansen CR, Pressler T. Cystic fibrosis - an example of personalized and precision medicine. APMIS 2019;127:352-60. [PMID: 30761610 DOI: 10.1111/apm.12915] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
5 Langton Hewer SC, Smyth AR, Brown M, Jones AP, Hickey H, Kenna D, Ashby D, Thompson A, Sutton L, Clayton D, Arch B, Tanajewski Ł, Berdunov V, Williamson PR. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT. Health Technol Assess 2021;25:1-128. [PMID: 34806975 DOI: 10.3310/hta25650] [Reference Citation Analysis]
6 Taccetti G, Francalanci M, Pizzamiglio G, Messore B, Carnovale V, Cimino G, Cipolli M. Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives. Antibiotics (Basel) 2021;10:338. [PMID: 33810116 DOI: 10.3390/antibiotics10030338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fiel SB, Roesch EA. The Use of Tobramycin for Pseudomonas aeruginosa: A Review. Expert Rev Respir Med 2022. [PMID: 35320051 DOI: 10.1080/17476348.2022.2057951] [Reference Citation Analysis]
8 Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel P, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-hamblett N, Kashirskaya N, Kerem E, Mathew JL, Mckone EF, Naehrlich L, Nasr SZ, Oates GR, O'neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. The future of cystic fibrosis care: a global perspective. The Lancet Respiratory Medicine 2020;8:65-124. [DOI: 10.1016/s2213-2600(19)30337-6] [Cited by in Crossref: 183] [Cited by in F6Publishing: 82] [Article Influence: 91.5] [Reference Citation Analysis]
9 Sinclair G, McMahon V, Schellenberg A, Nelson TN, Chilvers M, Vallance H. Performance of a Three-Tier (IRT-DNA-IRT) Cystic Fibrosis Screening Algorithm in British Columbia. Int J Neonatal Screen 2020;6:46. [PMID: 33073036 DOI: 10.3390/ijns6020046] [Reference Citation Analysis]
10 Viñado C, Girón RM, Ibáñez E, García-Ortega A, Pérez I, Polanco D, Pemán J, Solé A. Filamentous fungi in the airway of patients with cystic fibrosis: Just spectators? Rev Iberoam Micol 2021:S1130-1406(21)00036-X. [PMID: 34535388 DOI: 10.1016/j.riam.2021.03.005] [Reference Citation Analysis]
11 Oh J, McGarry DP, Joseph N, Peppers B, Hostoffer R. Salivary IgA deficiency in a patient with cystic fibrosis (genotype M470V/V520F). Ann Allergy Asthma Immunol 2018;121:619-20. [PMID: 30392531 DOI: 10.1016/j.anai.2018.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 De Sutter P, Gasthuys E, Van Braeckel E, Schelstraete P, Van Biervliet S, Van Bocxlaer J, Vermeulen A. Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019. Clin Pharmacokinet 2020;59:1551-73. [DOI: 10.1007/s40262-020-00932-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Dayasiri K, Hull J, Rao S. NICE guidance on diagnosis and management of cystic fibrosis. Arch Dis Child Educ Pract Ed 2021;106:31-4. [PMID: 32447278 DOI: 10.1136/archdischild-2019-316882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Addy C, Caskey S, Downey D. Gram negative infections in cystic fibrosis: a review of preventative and treatment options. Expert Opinion on Orphan Drugs 2020;8:11-26. [DOI: 10.1080/21678707.2020.1713748] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Castaldo A, Iacotucci P, Carnovale V, Cimino R, Liguori R, Comegna M, Raia V, Corso G, Castaldo G, Gelzo M. Salivary Cytokines and Airways Disease Severity in Patients with Cystic Fibrosis. Diagnostics (Basel) 2020;10:E222. [PMID: 32326546 DOI: 10.3390/diagnostics10040222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respir Med 2019;7:855-69. [PMID: 31405826 DOI: 10.1016/S2213-2600(19)30185-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 8.7] [Reference Citation Analysis]
17 Mésinèle J, Ruffin M, Kemgang A, Guillot L, Boëlle PY, Corvol H. Risk factors for Pseudomonas aeruginosa airway infection and lung function decline in children with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)01422-3. [PMID: 34629287 DOI: 10.1016/j.jcf.2021.09.017] [Reference Citation Analysis]
18 Gruber W, Welsner M, Dillenhöfer S, Olivier M, Koerner-Rettberg C, Sutharsan S, Taube C, Mellies U, Stehling F. Health-Related and Motor Performance-Related Fitness and Physical Activity Among Youth With Cystic Fibrosis. Percept Mot Skills 2021;128:2097-116. [PMID: 34338055 DOI: 10.1177/00315125211036415] [Reference Citation Analysis]
19 Taylor SL, Leong LEX, Ivey KL, Wesselingh S, Grimwood K, Wainwright CE, Rogers GB; Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study group. Total bacterial load, inflammation, and structural lung disease in paediatric cystic fibrosis. J Cyst Fibros 2020;19:923-30. [PMID: 32199729 DOI: 10.1016/j.jcf.2020.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Pleskova J, Koucky V, Medunova K, Vlckova B, Smolikova L, Pohunek P. Reflex zone stimulation reduces ventilation inhomogeneity in cystic fibrosis: A randomised controlled cross-over study. Pediatr Pulmonol 2021;56:1558-65. [PMID: 33656249 DOI: 10.1002/ppul.25350] [Reference Citation Analysis]
21 Colombo C, Cipolli M, Daccò V, Medino P, Alghisi F, Ambroni M, Badolato R, Battistini F, Bignamini E, Casciaro R, Ciciriello F, Collura M, Comello I, Francalanci M, Ficili F, Folino A, Leonardi S, Leonetti G, Lucanto MC, Lucca F, Maschio M, Mencarini V, Messore B, Pisi G, Pizzamiglio G, Poli P, Raia V, Riberi L, Ros M, Rotolo N, Sepe A, Taccetti G, Vitullo P, Alicandro G. Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society. Infection 2021. [PMID: 34874541 DOI: 10.1007/s15010-021-01737-z] [Reference Citation Analysis]
22 Page A, Goldenberg A, Matthews AL. Lived experiences of individuals with cystic fibrosis on CFTR-modulators. BMC Pulm Med 2022;22. [DOI: 10.1186/s12890-022-01825-2] [Reference Citation Analysis]
23 Somayaji R, Nichols DP, Bell SC. Cystic fibrosis - Ten promising therapeutic approaches in the current era of care. Expert Opin Investig Drugs 2020;29:1107-24. [PMID: 32744089 DOI: 10.1080/13543784.2020.1805733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Agostoni C, Bertolozzi G, Cantoni B, Colombo C, Montini G, Marchisio P. Three months of COVID-19 in a pediatric setting in the center of Milan. Pediatr Res 2021;89:1572-7. [PMID: 32854109 DOI: 10.1038/s41390-020-01108-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Xie M, Wang Z, Wan X, Weng J, Tu M, Mei J, Wang Z, Du X, Wang L, Chen C. Crosslinking effects of branched PEG on decellularized lungs of rats for tissue engineering. J Biomater Appl 2020;34:965-74. [PMID: 31690161 DOI: 10.1177/0885328219885068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Postek M, Walicka-serzysko K, Milczewska J, Sands D. What Is Most Suitable for Children With Cystic Fibrosis—The Relationship Between Spirometry, Oscillometry, and Multiple Breath Nitrogen Washout. Front Pediatr 2022;9:692949. [DOI: 10.3389/fped.2021.692949] [Reference Citation Analysis]
27 McLean SA, Cullen L, Gardam DJ, Schofield CJ, Laucirica DR, Sutanto EN, Ling KM, Stick SM, Peacock CS, Kicic A, Garratt LW, On Behalf Of Arest Cf, Waerp. Cystic Fibrosis Clinical Isolates of Aspergillus fumigatus Induce Similar Muco-inflammatory Responses in Primary Airway Epithelial Cells. Pathogens 2021;10:1020. [PMID: 34451484 DOI: 10.3390/pathogens10081020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Doull I, Course CW, Hanks RE, Southern KW, Forton JT, Thia LP, Moat SJ. Cystic fibrosis newborn screening: the importance of bloodspot sample quality. Arch Dis Child 2021;106:253-7. [PMID: 32859613 DOI: 10.1136/archdischild-2020-318999] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Tait JR, Bilal H, Kim TH, Oh A, Peleg AY, Boyce JD, Oliver A, Bergen PJ, Nation RL, Landersdorfer CB. Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model. J Glob Antimicrob Resist 2021;26:55-63. [PMID: 34023531 DOI: 10.1016/j.jgar.2021.04.021] [Reference Citation Analysis]
30 Simões FB, Quaresma MC, Clarke LA, Silva IA, Pankonien I, Railean V, Kmit A, Amaral MD. TMEM16A chloride channel does not drive mucus production. Life Sci Alliance 2019;2:e201900462. [PMID: 31732694 DOI: 10.26508/lsa.201900462] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
31 Delfino D, Mori G, Rivetti C, Grigoletto A, Bizzotto G, Cavozzi C, Malatesta M, Cavazzini D, Pasut G, Percudani R. Actin-Resistant DNase1L2 as a Potential Therapeutics for CF Lung Disease. Biomolecules 2021;11:410. [PMID: 33802146 DOI: 10.3390/biom11030410] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Gokdemir Y, Karadag BT. Sweat Testing and Recent Advances. Front Pediatr 2021;9:649904. [PMID: 34017807 DOI: 10.3389/fped.2021.649904] [Reference Citation Analysis]
33 Atag E, Krivec U, Ersu R. Non-invasive Ventilation for Children With Chronic Lung Disease. Front Pediatr 2020;8:561639. [PMID: 33262959 DOI: 10.3389/fped.2020.561639] [Reference Citation Analysis]
34 Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019;394:1940-8. [PMID: 31679946 DOI: 10.1016/S0140-6736(19)32597-8] [Cited by in Crossref: 265] [Cited by in F6Publishing: 110] [Article Influence: 88.3] [Reference Citation Analysis]
35 Voldby C, Green K, Philipsen L, Sandvik RM, Skov M, Buchvald F, Pressler T, Nielsen KG. Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)00039-4. [PMID: 33619014 DOI: 10.1016/j.jcf.2021.02.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Ringshausen FC, Hellmuth T, Dittrich AM. [Evidence-based treatment of cystic fibrosis]. Internist (Berl) 2020;61:1212-29. [PMID: 33201261 DOI: 10.1007/s00108-020-00896-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Huang T, Li C, Liu D. Recurrent Cough and Expectoration for 10 Years: A Case Report. Glob Pediatr Health 2019;6:2333794X19833725. [PMID: 30993151 DOI: 10.1177/2333794X19833725] [Reference Citation Analysis]
38 Blin T, Flament T, Mankikian J, Chambellan A, Marchand-Adam S, Plantier L. Impulse oscillometry and spirometry measurements relative to personal best values at the time of acute exacerbations of cystic fibrosis in adults. Clin Physiol Funct Imaging 2021;41:76-84. [PMID: 33010097 DOI: 10.1111/cpf.12668] [Reference Citation Analysis]
39 Rogers GB, Taylor SL, Hoffman LR, Burr LD. The impact of CFTR modulator therapies on CF airway microbiology. J Cyst Fibros 2020;19:359-64. [PMID: 31416774 DOI: 10.1016/j.jcf.2019.07.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
40 Scotet V, Gutierrez H, Farrell PM. Newborn Screening for CF across the Globe-Where Is It Worthwhile? Int J Neonatal Screen 2020;6:18. [PMID: 33073015 DOI: 10.3390/ijns6010018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
41 Zeyda M, Schanzer A, Basek P, Bauer V, Eber E, Ellemunter H, Kallinger M, Riedler J, Thir C, Wadlegger F, Zacharasiewicz A, Renner S. Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters. Diagnostics (Basel) 2021;11:299. [PMID: 33668470 DOI: 10.3390/diagnostics11020299] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Frey DL, Boutin S, Dittrich SA, Graeber SY, Stahl M, Wege S, Herth FJF, Sommerburg O, Schultz C, Mall MA, Dalpke AH. Relationship between airway dysbiosis, inflammation and lung function in adults with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(20)30954-1. [PMID: 33431308 DOI: 10.1016/j.jcf.2020.12.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
43 Kapnadak SG, Dimango E, Hadjiliadis D, Hempstead SE, Tallarico E, Pilewski JM, Faro A, Albright J, Benden C, Blair S, Dellon EP, Gochenour D, Michelson P, Moshiree B, Neuringer I, Riedy C, Schindler T, Singer LG, Young D, Vignola L, Zukosky J, Simon RH. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. Journal of Cystic Fibrosis 2020;19:344-54. [DOI: 10.1016/j.jcf.2020.02.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
44 Pereira SV, Ribeiro JD, Ribeiro AF, Bertuzzo CS, Marson FAL. Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools. Sci Rep 2019;9:6234. [PMID: 30996306 DOI: 10.1038/s41598-019-42404-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
45 Hall K, Maxwell L, Cobb R, Steele M, Chambers R, Roll M, Bell SC, Kuys S. Physiotherapy service provision in a specialist adult cystic fibrosis service: A pre-post design study with the inclusion of an allied health assistant. Chron Respir Dis 2021;18:14799731211017895. [PMID: 34142582 DOI: 10.1177/14799731211017895] [Reference Citation Analysis]
46 Walicka‐serzysko K, Postek M, Milczewska J, Sands D. Lung function deterioration in school children with cystic fibrosis. Pediatr Pulmonol 2020;55:3030-8. [DOI: 10.1002/ppul.25013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Nusbaum K, Filigno SS, Feldstein J, Hente E, Koch E, Mullen L, Weiland J, Boat T, Siracusa C. Assessing and responding to stress related to pulmonary function testing in cystic fibrosis through quality improvement. Pediatr Pulmonol 2020;55:1139-46. [PMID: 32040891 DOI: 10.1002/ppul.24673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Imrei M, Németh D, Szakács Z, Hegyi P, Kiss S, Alizadeh H, Dembrovszky F, Pázmány P, Bajor J, Párniczky A. Increased Prevalence of Celiac Disease in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis. J Pers Med 2021;11:859. [PMID: 34575636 DOI: 10.3390/jpm11090859] [Reference Citation Analysis]
49 Cirilli N, Southern K, Barben J, Vermeulen F, Munck A, Wilschanski M, Nguyen-khoa T, Aralica M, Simmonds N, De Wachter E. Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programme. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.01.004] [Reference Citation Analysis]
50 Hatziagorou E, Kampouras A, Avramidou V, Toulia I, Chrysochoou EA, Galogavrou M, Kirvassilis F, Tsanakas J. Toward the Establishment of New Clinical Endpoints for Cystic Fibrosis: The Role of Lung Clearance Index and Cardiopulmonary Exercise Testing. Front Pediatr 2021;9:635719. [PMID: 33718306 DOI: 10.3389/fped.2021.635719] [Reference Citation Analysis]
51 Gelzo M, Iacotucci P, Sica C, Liguori R, Comegna M, Carnovale V, Dello Russo A, Corso G, Castaldo G. Influence of pancreatic status on circulating plasma sterols in patients with cystic fibrosis. Clin Chem Lab Med 2020;58:1725-30. [PMID: 32083440 DOI: 10.1515/cclm-2019-1112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
52 Coverstone AM, Ferkol TW. Early Diagnosis and Intervention in Cystic Fibrosis: Imagining the Unimaginable. Front Pediatr 2020;8:608821. [PMID: 33505947 DOI: 10.3389/fped.2020.608821] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Lommatzsch ST. Infection prevention and chronic disease management in cystic fibrosis and noncystic fibrosis bronchiectasis. Ther Adv Respir Dis 2020;14:1753466620905272. [PMID: 32160809 DOI: 10.1177/1753466620905272] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Holland P, Jahnke N. Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2021;6:CD002007. [PMID: 34159577 DOI: 10.1002/14651858.CD002007.pub5] [Reference Citation Analysis]
55 Curran M, Tierney AC, Button B, Collins L, Kennedy L, McDonnell C, Casserly B, Cahalan R. The effectiveness of exercise interventions to increase physical activity in Cystic Fibrosis: A systematic review. J Cyst Fibros 2021:S1569-1993(21)02110-X. [PMID: 34753671 DOI: 10.1016/j.jcf.2021.10.008] [Reference Citation Analysis]
56 Lafoeste H, Regard L, Martin C, Chassagnon G, Burgel P. Complications aiguës respiratoires et non respiratoires chez l’adulte mucoviscidosique. Revue de Pneumologie Clinique 2018;74:267-78. [DOI: 10.1016/j.pneumo.2018.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Schütz K, Kontsendorn J, Janzen N, Fuge J, Grewendorf S, Klemann C, Happle C, Junge S, Rudolf I, Dopfer C, Sedlacek L, Renz D, Hansen G, Dittrich A. The First 4 Years – Outcome of Children Identified by Newborn Screening for CF in Germany. Klin Padiatr. [DOI: 10.1055/a-1700-5105] [Reference Citation Analysis]
58 Paul GR, Bai S, Jackson K, McCoy KS. Aquagenic wrinkling in children under two years of age: Could this be a potential clinical referral tool for cystic fibrosis among non-screened populations? J Cyst Fibros 2021:S1569-1993(21)00112-0. [PMID: 34016560 DOI: 10.1016/j.jcf.2021.04.002] [Reference Citation Analysis]
59 Zyryanov SK, Ushkalova EA, Kondratyeva EI, Butranova OI, Kondakova YA. Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis. Biomedicines 2022;10:1050. [DOI: 10.3390/biomedicines10051050] [Reference Citation Analysis]
60 Neri LCL, Simon MISDS, Ambrósio VLS, Barbosa E, Garcia MF, Mauri JF, Guirau RR, Neves MA, Cunha CAP, Nogueira MC, Alves ACDC, Gurmini J, Servidoni MF, Epifanio M, Athanazio R; Grupo de Trabalho das Diretrizes Brasileiras de Nutrição em Fibrose Cística. Brazilian Guidelines for Nutrition in Cystic Fibrosis. Einstein (Sao Paulo) 2022;20:eRW5686. [PMID: 35384985 DOI: 10.31744/einstein_journal/2022RW5686] [Reference Citation Analysis]
61 Flume PA, Vandevanter DR. Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes. Eur Respir J 2020;55:2000105. [DOI: 10.1183/13993003.00105-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Jung A, Orenti A, Dunlevy F, Aleksejeva E, Bakkeheim E, Bobrovnichy V, Carr SB, Colombo C, Corvol H, Cosgriff R, Daneau G, Dogru D, Drevinek P, Vukic AD, Fajac I, Fox A, Fustik S, Gulmans V, Harutyunyan S, Hatziagorou E, Kasmi I, Kayserová H, Kondratyeva E, Krivec U, Makukh H, Malakauskas K, McKone EF, Mei-Zahav M, de Monestrol I, Olesen HV, Padoan R, Parulava T, Pastor-Vivero MD, Pereira L, Petrova G, Pfleger A, Pop L, van Rens JG, Rodic M, Schlesser M, Storms V, Turcu O, Woz Niacki L, Yiallouros P, Zolin A, Downey DG, Naehrlich L. Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe. ERJ Open Res 2021;7:00411-2021. [PMID: 34984210 DOI: 10.1183/23120541.00411-2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Martinez-Millana A, Zettl A, Floch J, Calvo-Lerma J, Sevillano JL, Ribes-Koninckx C, Traver V. The Potential of Self-Management mHealth for Pediatric Cystic Fibrosis: Mixed-Methods Study for Health Care and App Assessment. JMIR Mhealth Uhealth 2019;7:e13362. [PMID: 30998222 DOI: 10.2196/13362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
64 Havermans T, Willem L. Prevention of anxiety and depression in cystic fibrosis. Current Opinion in Pulmonary Medicine 2019;25:654-9. [DOI: 10.1097/mcp.0000000000000617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Van Schandevyl G, Casimir G, Hanssens L. A medication adherence-enhancing simulation intervention in pediatric cystic fibrosis. J Child Health Care 2021;:13674935211013924. [PMID: 33928824 DOI: 10.1177/13674935211013924] [Reference Citation Analysis]
66 Sareen A, Ramphul M, Bhatt JM. It's not all about inhaled treatment: challenges with oral therapy in paediatric respiratory medicine. Breathe (Sheff) 2021;17:210005. [PMID: 34295409 DOI: 10.1183/20734735.0005-2021] [Reference Citation Analysis]
67 Birch L, Lithander FE, Hewer SL, Harriman K, Hamilton-Shield J, Perry R. Dietary interventions for managing glucose abnormalities in cystic fibrosis: a systematic review protocol. Syst Rev 2018;7:98. [PMID: 30021636 DOI: 10.1186/s13643-018-0757-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
68 Delfino E, Del Puente F, Briano F, Sepulcri C, Giacobbe DR. Respiratory Fungal Diseases in Adult Patients With Cystic Fibrosis. Clin Med Insights Circ Respir Pulm Med 2019;13:1179548419849939. [PMID: 31205434 DOI: 10.1177/1179548419849939] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
69 Bergougnoux A, Lopez M, Girodon E. The Role of Extended CFTR Gene Sequencing in Newborn Screening for Cystic Fibrosis. Int J Neonatal Screen 2020;6:23. [PMID: 33073020 DOI: 10.3390/ijns6010023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Gramer G, Brockow I, Labitzke C, Fang-Hoffmann J, Beivers A, Feyh P, Hoffmann GF, Nennstiel U, Sommerburg O. Implementing a tracking system for confirmatory diagnostic results after positive newborn screening for cystic fibrosis-implications for process quality and patient care. Eur J Pediatr 2021;180:1145-55. [PMID: 33104872 DOI: 10.1007/s00431-020-03849-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Sheahan KP, Glynn D, Joyce S, Maher MM, Boland F, O'Connor OJ. Best Practices: Imaging Strategies for Reduced-Dose Chest CT in the Management of Cystic Fibrosis-Related Lung Disease. AJR Am J Roentgenol 2021;217:304-13. [PMID: 34076456 DOI: 10.2214/AJR.19.22694] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Dediu M, Ciuca IM, Marc MS, Boeriu E, Pop LL. Factors Influencing Lung Function in Patients with Cystic Fibrosis in Western Romania. J Multidiscip Healthc 2021;14:1423-9. [PMID: 34163170 DOI: 10.2147/JMDH.S313209] [Reference Citation Analysis]
73 Barben J, Chudleigh J. Processing Newborn Bloodspot Screening Results for CF. Int J Neonatal Screen 2020;6:25. [PMID: 33073022 DOI: 10.3390/ijns6020025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Mercier J, Calmel C, Mésinèle J, Sutanto E, Merabtene F, Longchampt E, Sage E, Kicic A, Boëlle P, Corvol H, Ruffin M, Guillot L. SLC6A14 Impacts Cystic Fibrosis Lung Disease Severity via mTOR and Epithelial Repair Modulation. Front Mol Biosci 2022;9:850261. [DOI: 10.3389/fmolb.2022.850261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Mathy V, Grohs P, Compain F. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis. J Med Microbiol 2018;67:1217-20. [PMID: 30016231 DOI: 10.1099/jmm.0.000801] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
76 Shteinberg M, Flume PA, Chalmers JD. Is bronchiectasis really a disease? Eur Respir Rev 2020;29:190051. [PMID: 31996354 DOI: 10.1183/16000617.0051-2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 da Silva Filho LVRF, Zampoli M, Cohen-Cymberknoh M, Kabra SK. Cystic fibrosis in low and middle-income countries (LMIC): A view from four different regions of the world. Paediatr Respir Rev 2021;38:37-44. [PMID: 32826173 DOI: 10.1016/j.prrv.2020.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
78 Terlizzi V, Masi E, Francalanci M, Taccetti G, Innocenti D. Hypertonic saline in people with cystic fibrosis: review of comparative studies and clinical practice. Ital J Pediatr 2021;47:168. [PMID: 34362426 DOI: 10.1186/s13052-021-01117-1] [Reference Citation Analysis]
79 Gartner S, Mondéjar-lópez P, Asensio de la Cruz Ó. Protocolo de seguimiento de pacientes con fibrosis quística diagnosticados por cribado neonatal. Anales de Pediatría 2019;90:251.e1-251.e10. [DOI: 10.1016/j.anpedi.2018.11.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
80 Poore TS, Taylor-Cousar JL, Zemanick ET. Cardiovascular complications in cystic fibrosis: A review of the literature. J Cyst Fibros 2021:S1569-1993(21)00126-0. [PMID: 34140249 DOI: 10.1016/j.jcf.2021.04.016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Naehrlich L. The Changing Face of Cystic Fibrosis and Its Implications for Screening. Int J Neonatal Screen 2020;6:54. [PMID: 33123635 DOI: 10.3390/ijns6030054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
82 Sommerburg O, Stahl M, Hämmerling S, Gramer G, Muckenthaler MU, Okun J, Kohlmüller D, Happich M, Kulozik AE, Mall MA, Hoffmann GF. Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety net: Results of the Southwest German CFNBS pilot study. J Cyst Fibros 2021:S1569-1993(21)02109-3. [PMID: 34764021 DOI: 10.1016/j.jcf.2021.10.007] [Reference Citation Analysis]
83 Coppolo DP, Schloss J, Suggett JA, Mitchell JP. Non-Pharmaceutical Techniques for Obstructive Airway Clearance Focusing on the Role of Oscillating Positive Expiratory Pressure (OPEP): A Narrative Review. Pulm Ther 2021. [PMID: 34860355 DOI: 10.1007/s41030-021-00178-1] [Reference Citation Analysis]
84 Ramos KJ, Smith PJ, McKone EF, Pilewski JM, Lucy A, Hempstead SE, Tallarico E, Faro A, Rosenbluth DB, Gray AL, Dunitz JM; CF Lung Transplant Referral Guidelines Committee. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros 2019;18:321-33. [PMID: 30926322 DOI: 10.1016/j.jcf.2019.03.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 40] [Article Influence: 19.7] [Reference Citation Analysis]
85 Chudleigh J, Chinnery H. Psychological Impact of NBS for CF. Int J Neonatal Screen 2020;6:27. [PMID: 33073024 DOI: 10.3390/ijns6020027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
86 van der Meer R, Touw DJ, Heijerman HGM. Prevention of drug-related complications in cystic fibrosis. Curr Opin Pulm Med 2019;25:666-73. [PMID: 31503211 DOI: 10.1097/MCP.0000000000000625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Gerzon FLGR, Jöbsis Q, Bannier MAGE, Winkens B, Dompeling E. Discrepancy between Lung Function Measurements at Home and in the Hospital in Children with Asthma and CF. J Clin Med 2020;9:E1617. [PMID: 32466623 DOI: 10.3390/jcm9061617] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
88 Bruderer T, Gaisl T, Gaugg MT, Nowak N, Streckenbach B, Müller S, Moeller A, Kohler M, Zenobi R. On-Line Analysis of Exhaled Breath Focus Review. Chem Rev 2019;119:10803-28. [PMID: 31594311 DOI: 10.1021/acs.chemrev.9b00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 12.3] [Reference Citation Analysis]
89 Meerburg JJ, Albasri M, van der Wiel EC, Andrinopoulou ER, van der Eerden MM, Majoor CJ, Arets HGM, Heijerman HGM, Tiddens HAWM. Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough. Pediatr Pulmonol 2019;54:1794-800. [PMID: 31393073 DOI: 10.1002/ppul.24467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
90 Rossitto M, Tabarini P, Tuccio Guarna Assanti V, Montemitro E, Pompilio A, Fiscarelli EV. Environmental Microbial Contamination during Cystic Fibrosis Group-Based Psychotherapy. Int J Environ Res Public Health 2021;18:1142. [PMID: 33525434 DOI: 10.3390/ijerph18031142] [Reference Citation Analysis]
91 Kunz AS, Weng AM, Wech T, Knapp J, Petritsch B, Hebestreit H, Bley TA, Köstler H, Veldhoen S. Non-contrast pulmonary perfusion MRI in patients with cystic fibrosis. Eur J Radiol 2021;139:109653. [PMID: 33838429 DOI: 10.1016/j.ejrad.2021.109653] [Reference Citation Analysis]
92 Kamusheva M, Dimitrova M, Tachkov K, Petrova G, Mitkova Z. Pharmacotherapeutic Patterns and Patients' Access to Pharmacotherapy for Some Rare Diseases in Bulgaria - A Pilot Comparative Study. Front Pharmacol 2021;12:695181. [PMID: 34349654 DOI: 10.3389/fphar.2021.695181] [Reference Citation Analysis]
93 Kreslová M, Sýkorová A, Bittenglová R, Schwarz J, Pomahačová R, Jehlička P, Kobr J, Trefil L, Sýkora J. Age-Related Progression of Microvascular Dysfunction in Cystic Fibrosis: New Detection Ways and Clinical Outcomes. Physiol Res 2021. [DOI: 10.33549//physiolres.934743] [Reference Citation Analysis]
94 Walicka‐serzysko K, Postek M, Milczewska J, Sands D. Change in lung clearance index with microbiological status in children with cystic fibrosis. Pediatric Pulmonology 2019;54:729-36. [DOI: 10.1002/ppul.24278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
95 Acosta N, Thornton CS, Surette MG, Somayaji R, Rossi L, Rabin HR, Parkins MD. Azithromycin and the microbiota of cystic fibrosis sputum. BMC Microbiol 2021;21:96. [PMID: 33784986 DOI: 10.1186/s12866-021-02159-5] [Reference Citation Analysis]
96 Smirnikhina SA, Kondrateva EV, Adilgereeva EP, Anuchina AA, Zaynitdinova MI, Slesarenko YS, Ershova AS, Ustinov KD, Yasinovsky MI, Amelina EL, Voronina ES, Yakushina VD, Tabakov VY, Lavrov AV. P.F508del editing in cells from cystic fibrosis patients. PLoS One 2020;15:e0242094. [PMID: 33175893 DOI: 10.1371/journal.pone.0242094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Botti M, Terlizzi V, Francalanci M, Dolce D, Cavicchi MC, Neri AS, Galici V, Mergni G, Zavataro L, Centrone C, Festini F, Taccetti G. Cystic fibrosis in Tuscany: evolution of newborn screening strategies over time to the present. Ital J Pediatr 2021;47:2. [PMID: 33407736 DOI: 10.1186/s13052-020-00948-8] [Reference Citation Analysis]
98 Pailhoriès H, Herrmann JL, Velo-Suarez L, Lamoureux C, Beauruelle C, Burgel PR, Héry-Arnaud G. Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome. Eur Respir Rev 2022;31:210259. [PMID: 35613743 DOI: 10.1183/16000617.0259-2021] [Reference Citation Analysis]
99 Fustik S, Anastasovska V, Plaseska-Karanfilska D, Stamatova A, Spirevska L, Pesevska M, Terzikj M, Vujovic M. Two Years of Newborn Screening for Cystic Fibrosis in North Macedonia: First Experience. Balkan J Med Genet 2021;24:41-6. [PMID: 34447658 DOI: 10.2478/bjmg-2021-0015] [Reference Citation Analysis]
100 Körner RW, van Koningsbruggen-rietschel S. 7/w mit chronischem Husten: Vorbereitung auf die Facharztprüfung: Fall 57. Monatsschr Kinderheilkd. [DOI: 10.1007/s00112-022-01456-1] [Reference Citation Analysis]
101 Curran M, Tierney A, Collins L, Kennedy L, McDonnell C, Sheikhi A, Walsh C, Casserly B, Cahalan R. Accuracy of the ActivPAL and Fitbit Charge 2 in measuring step count in Cystic Fibrosis. Physiother Theory Pract 2021;:1-11. [PMID: 34369283 DOI: 10.1080/09593985.2021.1962463] [Reference Citation Analysis]
102 Durieu I, Dalon F, Reynaud Q, Lemonnier L, Dehillotte C, Bérard M, Walther D, Viprey M, Van Ganse E, Belhassen M. Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)00107-7. [PMID: 33865726 DOI: 10.1016/j.jcf.2021.03.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Toin T, Reynaud Q, Denis A, Durieu I, Mainguy C, Llerena C, Pin I, Touzet S, Reix P. HOMA indices as screening tests for cystic fibrosis-related diabetes. J Cyst Fibros 2021:S1569-1993(21)00161-2. [PMID: 34090803 DOI: 10.1016/j.jcf.2021.05.010] [Reference Citation Analysis]
104 Stahl M. [Clinical presentation of lung disease in cystic fibrosis]. Radiologe 2020;60:774-80. [PMID: 32761355 DOI: 10.1007/s00117-020-00728-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Calthorpe RJ, Smyth AR. Telehealth after the pandemic: Will the inverse care law apply? (Commentary). J Cyst Fibros 2021;20 Suppl 3:47-8. [PMID: 34521596 DOI: 10.1016/j.jcf.2021.08.023] [Reference Citation Analysis]
106 Gathercole K. Managing cystic fibrosis alongside children’s schooling: Family, nurse and teacher perspectives. J Child Health Care 2018;23:425-36. [DOI: 10.1177/1367493518814930] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
107 Curran M, Tierney AC, Collins L, Kennedy L, McDonnell C, Jurascheck AJ, Sheikhi A, Walsh C, Button B, Galvin R, Casserly B, Cahalan R. Steps Ahead: optimising physical activity in adults with cystic fibrosis: Study Protocol for a pilot randomised trial using wearable technology, goal setting and text message feedback. HRB Open Res 2020;3:21. [PMID: 33283151 DOI: 10.12688/hrbopenres.13025.3] [Reference Citation Analysis]
108 Pinto MC, Silva IAL, Figueira MF, Amaral MD, Lopes-Pacheco M. Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis. J Exp Pharmacol 2021;13:693-723. [PMID: 34326672 DOI: 10.2147/JEP.S255377] [Reference Citation Analysis]
109 Sörensen M, Khakimov B, Nurjadi D, Boutin S, Yi B, Dalpke AH, Eigenbrod T. Comparative evaluation of the effect of different growth media on in vitro sensitivity to azithromycin in multi-drug resistant Pseudomonas aeruginosa isolated from cystic fibrosis patients. Antimicrob Resist Infect Control 2020;9:197. [PMID: 33298147 DOI: 10.1186/s13756-020-00859-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 El Hassani M, Caissy JA, Marsot A. Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet 2021;60:447-70. [PMID: 33447944 DOI: 10.1007/s40262-020-00970-3] [Reference Citation Analysis]
111 Yiallouros PK, Matthaiou AΜ, Anagnostopoulou P, Kouis P, Libik M, Adamidi T, Eleftheriou A, Demetriou A, Ioannou P, Tanteles GA, Costi C, Fanis P, Macek M, Neocleous V, Phylactou LA. Demographic characteristics, clinical and laboratory features, and the distribution of pathogenic variants in the CFTR gene in the Cypriot cystic fibrosis (CF) population demonstrate the utility of a national CF patient registry. Orphanet J Rare Dis 2021;16:409. [PMID: 34600583 DOI: 10.1186/s13023-021-02049-z] [Reference Citation Analysis]
112 Daikos GL, da Cunha CA, Rossolini GM, Stone GG, Baillon-Plot N, Tawadrous M, Irani P. Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa. Antibiotics (Basel) 2021;10:1126. [PMID: 34572708 DOI: 10.3390/antibiotics10091126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Veldhoen S, Heidenreich JF, Metz C, Petritsch B, Benkert T, Hebestreit HU, Bley TA, Köstler H, Weng AM. Three-dimensional Ultrashort Echotime Magnetic Resonance Imaging for Combined Morphologic and Ventilation Imaging in Pediatric Patients With Pulmonary Disease. J Thorac Imaging 2021;36:43-51. [PMID: 32453280 DOI: 10.1097/RTI.0000000000000537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Elborn JS, Flume PA, Van Devanter DR, Procaccianti C. Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiol 2021. [PMID: 34384254 DOI: 10.2217/fmb-2021-0150] [Reference Citation Analysis]
115 Gurses HN, Ucgun H, Zeren M, Denizoglu Kulli H, Cakır E. Does the effect of comprehensive respiratory physiotherapy home-program differ in children with cystic fibrosis and non-cystic fibrosis bronchiectasis? Eur J Pediatr 2022. [PMID: 35595860 DOI: 10.1007/s00431-022-04509-5] [Reference Citation Analysis]
116 Bell SC, Elborn JS, Byrnes CA. Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention. Respirology 2018;23:1006-22. [PMID: 30207018 DOI: 10.1111/resp.13398] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
117 Goralski JL, Stewart NJ, Woods JC. Novel imaging techniques for cystic fibrosis lung disease. Pediatr Pulmonol 2021;56 Suppl 1:S40-54. [PMID: 32592531 DOI: 10.1002/ppul.24931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
118 Petrova NV, Kashirskaya NY, Vasilyeva TA, Kondratyeva EI, Zhekaite EK, Voronkova AY, Sherman VD, Galkina VA, Ginter EK, Kutsev SI, Marakhonov AV, Zinchenko RA. Analysis of CFTR Mutation Spectrum in Ethnic Russian Cystic Fibrosis Patients. Genes (Basel) 2020;11:E554. [PMID: 32429104 DOI: 10.3390/genes11050554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
119 Havermans T, Houben J, Vermeulen F, Boon M, Proesmans M, Lorent N, de Soir E, Vos R, Dupont L. The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients. J Cyst Fibros 2020;19:880-7. [PMID: 32768311 DOI: 10.1016/j.jcf.2020.07.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
120 Meltzer C, Gilljam M, Vikgren J, Norrlund RR, Vult von Steyern K, Båth M, Johnsson ÅA. Quantification of Pulmonary Pathology in Cystic Fibrosis-Comparison Between Digital Chest Tomosynthesis and Computed Tomography. Radiat Prot Dosimetry 2021:ncab017. [PMID: 33683309 DOI: 10.1093/rpd/ncab017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Sommerburg O, Hammermann J. Pancreatitis-Associated Protein in Neonatal Screening for Cystic Fibrosis: Strengths and Weaknesses. Int J Neonatal Screen 2020;6:28. [PMID: 33073025 DOI: 10.3390/ijns6020028] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Kulkarni H, Kansra S, Karande S. Cystic fibrosis revisited. J Postgrad Med 2019;65:193-6. [PMID: 31169132 DOI: 10.4103/jpgm.JPGM_263_18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
123 Eckerland M, Bock C, Olivier M, Pichlmaier L, Steindor M, Stehling F. Reducing the frequency of respiratory tract infections in severe neurological disorders by inhaled antibiotics: a retrospective data analysis. ERJ Open Res 2019;5:00149-2018. [PMID: 31360698 DOI: 10.1183/23120541.00149-2018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
124 Colombo C, Alicandro G, Daccò V, Consales A, Mosca F, Agostoni C, Giannì ML. Breastfeeding in Cystic Fibrosis: A Systematic Review on Prevalence and Potential Benefits. Nutrients 2021;13:3263. [PMID: 34579139 DOI: 10.3390/nu13093263] [Reference Citation Analysis]
125 Dunk R, Madge S. SARS-CoV-2 driving rapid change in adult cystic fibrosis services: the role of the clinical nurse specialist. BMJ Open Qual 2021;10:e001427. [PMID: 34642180 DOI: 10.1136/bmjoq-2021-001427] [Reference Citation Analysis]
126 Sommerburg O, Hämmerling S, Schneider SP, Okun J, Langhans CD, Leutz-Schmidt P, Wielpütz MO, Siems W, Gräber SY, Mall MA, Stahl M. CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis. Antioxidants (Basel) 2021;10:483. [PMID: 33808590 DOI: 10.3390/antiox10030483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Hollander-Kraaijeveld FM, Lindeman Y, de Roos NM, Burghard M, van de Graaf EA, Heijerman HGM. Non-fasting bioelectrical impedance analysis in cystic fibrosis: Implications for clinical practice and research. J Cyst Fibros 2020;19:153-8. [PMID: 31176668 DOI: 10.1016/j.jcf.2019.05.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
128 Meerburg JJ, Andrinopoulou ER, Bos AC, Shin H, van Straten M, Hamed K, Mastoridis P, Tiddens HAWM. Effect of Inspiratory Maneuvers on Lung Deposition of Tobramycin Inhalation Powder: A Modeling Study. J Aerosol Med Pulm Drug Deliv 2020;33:61-72. [PMID: 32073919 DOI: 10.1089/jamp.2019.1529] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
129 Prieur MG, Christon LM, Mueller A, Smith BA, Georgiopoulos AM, Boat TF, Filigno SS. Promoting emotional wellness in children with cystic fibrosis, Part I: Child and family resilience. Pediatr Pulmonol 2021;56 Suppl 1:S97-S106. [PMID: 32658376 DOI: 10.1002/ppul.24958] [Reference Citation Analysis]
130 Brown A, Jenkins L, Reid A, Leavy A, McDowell G, McIlroy C, Thompson A, McNaughten B. How to perform and interpret the sweat test. Arch Dis Child Educ Pract Ed 2020;105:230-5. [PMID: 31744807 DOI: 10.1136/archdischild-2018-316615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
131 Lopes-Pacheco M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol 2019;10:1662. [PMID: 32153386 DOI: 10.3389/fphar.2019.01662] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 31.5] [Reference Citation Analysis]
132 Walicka-Serzysko K, Peckova M, Noordhoek JJ, Sands D, Drevinek P. Insights into the cystic fibrosis care in Eastern Europe: Results of survey. J Cyst Fibros 2018;17:475-7. [PMID: 29681443 DOI: 10.1016/j.jcf.2018.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
133 Lopes-Pacheco M, Pedemonte N, Veit G. Discovery of CFTR modulators for the treatment of cystic fibrosis. Expert Opin Drug Discov 2021;16:897-913. [PMID: 33823716 DOI: 10.1080/17460441.2021.1912732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
134 Schönenberger KA, Reber E, Bally L, Geiser T, Lin D, Stanga Z. Nutritional assessment in adults with cystic fibrosis. Nutrition 2019;67-68:110518. [PMID: 31473521 DOI: 10.1016/j.nut.2019.05.010] [Reference Citation Analysis]
135 Kondratyeva E, Bukharova T, Efremova A, Melyanovskaya Y, Bulatenko N, Davydenko K, Filatova A, Skoblov M, Krasovsky S, Petrova N, Polyakov A, Adyan T, Amelina E, Shadrina V, Zhekaite E, Zodbinova A, Chernyak A, Zinchenko R, Kutsev S, Goldshtein D. Health Characteristics of Patients with Cystic Fibrosis whose Genotype Includes a Variant of the Nucleotide Sequence c.3140-16T>A and Functional Analysis of this Variant. Genes (Basel) 2021;12:837. [PMID: 34071719 DOI: 10.3390/genes12060837] [Reference Citation Analysis]
136 Shkeiri R, Saliba W, Stein N, Najjar R, Weber G, Dror SK, Mishan PS, Adir Y, Shteinberg M. Exploring factors associated with acquisition and chronicity of infection in bronchiectasis: A population-based study. Respir Med 2021;185:106487. [PMID: 34139580 DOI: 10.1016/j.rmed.2021.106487] [Reference Citation Analysis]
137 Silva GF, J Simmonds N, Roth Dalcin PT. Clinical characteristics and outcomes in adult cystic fibrosis patients with severe lung disease in Porto Alegre, southern Brazil. BMC Pulm Med 2020;20:194. [PMID: 32677921 DOI: 10.1186/s12890-020-01223-6] [Reference Citation Analysis]
138 Flume PA, Castellani C, Davies J. JCF Year in Review. J Cyst Fibros 2021;20:1-2. [PMID: 33526211 DOI: 10.1016/j.jcf.2021.01.004] [Reference Citation Analysis]
139 Mills R, Rautemaa-Richardson R, Wilkinson S, Patel L, Maitra A, Horsley A. Impact of airway Exophiala spp. on children with cystic fibrosis. J Cyst Fibros 2021;20:702-7. [PMID: 33775601 DOI: 10.1016/j.jcf.2021.03.012] [Reference Citation Analysis]
140 Sandvik RM, Kongstad T, Green K, Voldby C, Buchvald F, Skov M, Pressler T, Nielsen KG. Prospective longitudinal association between repeated multiple breath washout measurements and computed tomography scores in children with cystic fibrosis. J Cyst Fibros 2021;20:632-40. [PMID: 33028501 DOI: 10.1016/j.jcf.2020.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Armstrong RE, Frith L, Ulph FM, Southern KW. Constructing a Bioethical Framework to Evaluate and Optimise Newborn Bloodspot Screening for Cystic Fibrosis. Int J Neonatal Screen 2020;6:40. [PMID: 33073032 DOI: 10.3390/ijns6020040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
142 Foil KE, Powers A, Raraigh KS, Wallis K, Southern KW, Salinas D. The increasing challenge of genetic counseling for cystic fibrosis. J Cyst Fibros 2019;18:167-74. [PMID: 30527892 DOI: 10.1016/j.jcf.2018.11.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
143 McCarthy SD, González HE, Higgins BD. Future Trends in Nebulized Therapies for Pulmonary Disease. J Pers Med 2020;10:E37. [PMID: 32397615 DOI: 10.3390/jpm10020037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
144 Ekkelenkamp MB, Cantón R, Díez-Aguilar M, Tunney MM, Gilpin DF, Bernardini F, Dale GE, Elborn JS, Bayjanov JR, Fluit A. Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics. Antimicrob Agents Chemother 2020;64:e01541-19. [PMID: 31767727 DOI: 10.1128/AAC.01541-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
145 Liou TG, Kartsonaki C, Keogh RH, Adler FR. Evaluation of a five-year predicted survival model for cystic fibrosis in later time periods. Sci Rep 2020;10:6602. [PMID: 32313191 DOI: 10.1038/s41598-020-63590-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
146 Bonnet P, Le Gal S, Calderon E, Delhaes L, Quinio D, Robert-Gangneux F, Ramel S, Nevez G. Pneumocystis jirovecii in Patients With Cystic Fibrosis: A Review. Front Cell Infect Microbiol 2020;10:571253. [PMID: 33117730 DOI: 10.3389/fcimb.2020.571253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
147 Bilton D, Fajac I, Pressler T, Clancy JP, Sands D, Minic P, Cipolli M, Galeva I, Solé A, Quittner AL, Jumadilova Z, Ciesielska M, Konstan MW; CLEAR-110 Study Group. Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. J Cyst Fibros 2021:S1569-1993(21)00164-8. [PMID: 34144923 DOI: 10.1016/j.jcf.2021.05.013] [Reference Citation Analysis]
148 Holland LR, Hilton J, Cookson K, Heinsch M, Gilligan C, Wark P. Understanding motivation for Australian adolescents and young adults with cystic fibrosis: Modifiable factors to support self-management. Health Soc Care Community 2022. [PMID: 34997788 DOI: 10.1111/hsc.13714] [Reference Citation Analysis]
149 Baldissera M, Lewindon PJ, Ramm LE, Hartel GF, Mattiello R, Ramm GA. Advanced but not mild liver disease is a predictor of decreased survival in children with cystic fibrosis, with far greater impact in females: A 27-year real-life cohort study. J Cyst Fibros 2021:S1569-1993(21)02156-1. [PMID: 34949555 DOI: 10.1016/j.jcf.2021.11.015] [Reference Citation Analysis]
150 Er B, Çelebioğlu E, Yalçin E, Doğru D, Erden Aki Ö, Uzun Ö, Akova M, Özçelik U, Kiper N, Emri S. Factors associated with severe lung disease in an adult population with cystic fibrosis: a single-center experience. Turk J Med Sci 2020;50:945-52. [PMID: 32394679 DOI: 10.3906/sag-1912-101] [Reference Citation Analysis]
151 Schwarz C, Taccetti G, Burgel P, Mulrennan S. Tobramycin safety and efficacy review article. Respiratory Medicine 2022. [DOI: 10.1016/j.rmed.2022.106778] [Reference Citation Analysis]
152 Tejada S, Ramírez-estrada S, Forero CG, Gallego M, Soriano JB, Cardinal-fernández PA, Ehrmann S, Rello J. Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis. Antibiotics 2022;11:275. [DOI: 10.3390/antibiotics11020275] [Reference Citation Analysis]
153 Thornton CS. Body Mass Index and Clinical Outcomes in Persons Living With Cystic Fibrosis-Is Bigger Always Better? JAMA Netw Open 2022;5:e220749. [PMID: 35254436 DOI: 10.1001/jamanetworkopen.2022.0749] [Reference Citation Analysis]
154 Voldby C, Green K, Kongstad T, Ring AM, Sandvik RM, Skov M, Buchvald F, Pressler T, Nielsen KG. Lung clearance index-triggered intervention in children with cystic fibrosis - A randomised pilot study. J Cyst Fibros 2020;19:934-41. [PMID: 32576447 DOI: 10.1016/j.jcf.2020.06.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
155 Bilal H, Bergen PJ, Tait JR, Wallis SC, Peleg AY, Roberts JA, Oliver A, Nation RL, Landersdorfer CB. Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model. Antimicrob Agents Chemother 2020;64:e00469-20. [PMID: 32366710 DOI: 10.1128/AAC.00469-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Hong G, Desai S, Moss RB, Eschenhagen P, Quon BS, Schwarz C. Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey. J Cyst Fibros 2021:S1569-1993(21)01306-0. [PMID: 34332906 DOI: 10.1016/j.jcf.2021.07.008] [Reference Citation Analysis]
157 Keating CL, Zuckerman JB, Singh PK, McKevitt M, Gurtovaya O, Bresnik M, Marshall BC, Saiman L. Pseudomonas aeruginosa Susceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation. Antimicrob Agents Chemother 2021;65:e02327-20. [PMID: 33318007 DOI: 10.1128/AAC.02327-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Pourtois JD, Kratochvil MJ, Chen Q, Haddock NL, Burgener EB, De Leo GA, Bollyky PL. Filamentous Bacteriophages and the Competitive Interaction between Pseudomonas aeruginosa Strains under Antibiotic Treatment: a Modeling Study. mSystems 2021;6:e0019321. [PMID: 34156288 DOI: 10.1128/mSystems.00193-21] [Reference Citation Analysis]
159 Hewer SCL, Smyth AR, Brown M, Jones AP, Hickey H, Kenna D, Ashby D, Thompson A, Williamson PR; TORPEDO-CF study group. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Lancet Respir Med 2020;8:975-86. [PMID: 33007285 DOI: 10.1016/S2213-2600(20)30331-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
160 Chen Q, Shen Y, Xu H, Tang X, Yang H, Zhao S. Prognosis and treatment of 46 Chinese pediatric cystic fibrosis patients. BMC Pediatr 2021;21:329. [PMID: 34315429 DOI: 10.1186/s12887-021-02789-8] [Reference Citation Analysis]
161 Munck A, Cheillan D, Audrezet MP, Guenet D, Huet F. [Newborn screening for cystic fibrosis in France]. Med Sci (Paris) 2021;37:491-9. [PMID: 34003095 DOI: 10.1051/medsci/2021051] [Reference Citation Analysis]
162 Regard L, Lafoeste H, Martin C, Chassagnon G, Burgel PR. [Ageing with cystic fibrosis: Classical and emerging comorbidities in adults with cystic fibrosis]. Rev Pneumol Clin 2018;74:279-91. [PMID: 30316653 DOI: 10.1016/j.pneumo.2018.09.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
163 Blanco-Orive P, Del Corral T, Martín-Casas P, Ceniza-Bordallo G, López-de-Uralde-Villanueva I. Quality of life and exercise tolerance tools in children/adolescents with cystic fibrosis: Systematic review. Med Clin (Barc) 2021:S0025-7753(21)00441-3. [PMID: 34507821 DOI: 10.1016/j.medcli.2021.06.025] [Reference Citation Analysis]
164 Kazmerski TM, West NE, Jain R, Uluer A, Georgiopoulos AM, Aitken ML, Taylor-Cousar JL. Family-building and parenting considerations for people with cystic fibrosis. Pediatr Pulmonol 2021. [PMID: 34407321 DOI: 10.1002/ppul.25620] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Bevivino A, Bacci G, Drevinek P, Nelson MT, Hoffman L, Mengoni A. Deciphering the Ecology of Cystic Fibrosis Bacterial Communities: Towards Systems-Level Integration. Trends Mol Med 2019;25:1110-22. [PMID: 31439509 DOI: 10.1016/j.molmed.2019.07.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
166 Hoo ZH, Hitchcock L, Curley R, Wildman MJ. A comparison of the CFHH criteria against the Leeds criteria in determining the Pseudomonas aeruginosa status among adults with cystic fibrosis. Respir Med 2020;171:106103. [PMID: 32758991 DOI: 10.1016/j.rmed.2020.106103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
167 Colombo C, Nobili RM, Alicandro G. Challenges with optimizing nutrition in cystic fibrosis. Expert Rev Respir Med 2019;13:533-44. [PMID: 31094240 DOI: 10.1080/17476348.2019.1614917] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
168 McCarthy C, Clancy JP, Brewington J. Sweat Chloride Testing. JAMA 2019;321:701-2. [PMID: 30698611 DOI: 10.1001/jama.2018.21998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
169 Zybert K, Borawska-Kowalczyk U, Wozniacki L, Dawidziuk M, Ołtarzewski M, Sands D. Clinical complications in children with false-negative results in cystic fibrosis newborn screening. J Pediatr (Rio J) 2021:S0021-7557(21)00169-8. [PMID: 34953776 DOI: 10.1016/j.jped.2021.11.007] [Reference Citation Analysis]
170 Elidottir H, Diemer S, Eklund E, Hansen CR. Abnormal glucose tolerance and lung function in children with cystic fibrosis. Comparing oral glucose tolerance test and continuous glucose monitoring. J Cyst Fibros 2021;20:779-84. [PMID: 33478894 DOI: 10.1016/j.jcf.2021.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
171 Hoo ZH, Totton N, Waterhouse S, Lewis J, Girling C, Bradburn M, Arden MA, Whelan P, Ainsworth J, Dawson S, Millward S, Barnett K, Dewar J, Barr HL, Saini G, Shepherd E, Carroll M, Allenby MI, Daniels TV, Nightingale JA, Lowther M, Carolan C, Clarke C, Szczepanski R, Hutchings M, Edenborough FP, Curley R, Wildman MJ. Real-World Adherence Among Adults With Cystic Fibrosis Is Low: A Retrospective Analysis of the CFHealthHub Digital Learning Health System. Chest 2021:S0012-3692(21)01267-8. [PMID: 34186037 DOI: 10.1016/j.chest.2021.06.039] [Reference Citation Analysis]
172 Taccetti G, Botti M, Terlizzi V, Cavicchi MC, Neri AS, Galici V, Mergni G, Centrone C, Peroni DG, Festini F. Clinical and Genotypical Features of False-Negative Patients in 26 Years of Cystic Fibrosis Neonatal Screening in Tuscany, Italy. Diagnostics (Basel) 2020;10:E446. [PMID: 32630227 DOI: 10.3390/diagnostics10070446] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
173 Mursaloglu HH, Akın C, Yılmaz Yeğit C, Ergenekon AP, Suzer Uzunoglu B, Taştan G, Gökdemir Y, Erdem Eralp E, Karahasan Yağcı A, Karakoç F, Karadağ B. Comparison of intravenous and non-intravenous antibiotic regimens in eradication of P. aeruginosa and MRSA in cystic fibrosis. Pediatr Pulmonol 2021;56:3745-51. [PMID: 34436829 DOI: 10.1002/ppul.25646] [Reference Citation Analysis]
174 Ong T, Van Citters AD, Dowd C, Fullmer J, List R, Pai SA, Ren CL, Scalia P, Solomon GM, Sawicki GS. Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network. J Cyst Fibros 2021;20 Suppl 3:57-63. [PMID: 34930544 DOI: 10.1016/j.jcf.2021.08.035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Munck A, Southern KW, Castellani C, de Winter-de Groot KM, Gartner S, Kashirskaya N, Linnane B, Mayell SJ, Proesmans M, Sands D, Sommerburg O, Barben J. Defining key outcomes to evaluate performance of newborn screening programmes for cystic fibrosis. Journal of Cystic Fibrosis 2021;20:820-3. [DOI: 10.1016/j.jcf.2021.02.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
176 Ďurč P, Foret F, Homola L, Malá M, Pokojová E, Vinohradská H, Dastych M, Krausová D, Nagy D, Bede O, Dřevínek P, Skalická V, Kubáň P. Skin wipe test: A simple, inexpensive, and fast approach in the diagnosis of cystic fibrosis. Pediatr Pulmonol 2020;55:1653-60. [PMID: 32250037 DOI: 10.1002/ppul.24758] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
177 Rossi Norrlund R, Meltzer C, Söderman C, Johnsson ÅA, Vikgren J, Molnar D, Gilljam M, Båth M. Evaluation of Two Chest Tomosynthesis Cystic Fibrosis Scoring Systems Using High-Resolution Computed Tomography Brody Scoring as Reference. Radiat Prot Dosimetry 2021:ncab057. [PMID: 33948650 DOI: 10.1093/rpd/ncab057] [Reference Citation Analysis]
178 Gambazza S, Guarise R, Carta F, Ambrogi F, Mirabella M, Brivio A, Colombo C. Exercise capacity and ventilation inhomogeneity in cystic fibrosis: A cross-sectional study. Pediatr Pulmonol 2020;55:394-400. [PMID: 31943945 DOI: 10.1002/ppul.24525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
179 Burgel P, Durieu I, Chiron R, Mely L, Prevotat A, Murris-espin M, Porzio M, Abely M, Reix P, Marguet C, Macey J, Sermet-gaudelus I, Corvol H, Bui S, Biouhee T, Hubert D, Munck A, Lemonnier L, Dehillotte C, Silva JD, Paillasseur J, Martin C. Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. Journal of Cystic Fibrosis 2021;20:220-7. [DOI: 10.1016/j.jcf.2020.06.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
180 Tosco A, Castaldo A, Colombo C, Claut L, Carnovale V, Iacotucci P, Lucarelli M, Cimino G, Fabrizzi B, Caporelli N, Majo F, Ciciriello F, Padoan R, Poli P, Taccetti G, Centrone C, Casciaro R, Castellani C, Salvatore D, Colangelo C, Bonomi P, Castaldo G, Terlizzi V. Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype. J Cyst Fibros 2022:S1569-1993(22)00109-6. [PMID: 35523714 DOI: 10.1016/j.jcf.2022.04.020] [Reference Citation Analysis]
181 Bannier MAGE, van de Kant KDG, Jöbsis Q, Dompeling E. Feasibility and diagnostic accuracy of an electronic nose in children with asthma and cystic fibrosis. J Breath Res 2019;13:036009. [PMID: 30213921 DOI: 10.1088/1752-7163/aae158] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
182 Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet 2021;397:2195-211. [PMID: 34090606 DOI: 10.1016/S0140-6736(20)32542-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Frey DL, Bridson C, Dittrich S, Graeber SY, Stahl M, Wege S, Herth F, Sommerburg O, Schultz C, Dalpke A, Mall MA, Boutin S. Changes in Microbiome Dominance Are Associated With Declining Lung Function and Fluctuating Inflammation in People With Cystic Fibrosis. Front Microbiol 2022;13:885822. [DOI: 10.3389/fmicb.2022.885822] [Reference Citation Analysis]
184 Harindhanavudhi T, Wang Q, Dunitz J, Moran A, Moheet A. Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis. J Cyst Fibros 2020;19:139-45. [PMID: 31727452 DOI: 10.1016/j.jcf.2019.10.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
185 van der Haak N, King SJ, Crowder T, Kench A, Painter C, Saxby N; Nutrition Guidelines for Cystic Fibrosis in Australia and New Zealand Authorship Group and Interdisciplinary Steering Committee. Highlights from the nutrition guidelines for cystic fibrosis in Australia and New Zealand. J Cyst Fibros 2020;19:16-25. [PMID: 31175004 DOI: 10.1016/j.jcf.2019.05.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
186 Liou TG. The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease. Chest. 2019;155:605-616. [PMID: 30359614 DOI: 10.1016/j.chest.2018.10.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
187 Kamp JC, Fuge J, Ringshausen FC, Grote-Koska D, Brand K, Graalmann L, Vonberg RP, Welte T, Rademacher J. Pharmacokinetics of Meropenem in People with Cystic Fibrosis-A Proof of Concept Clinical Trial. Antibiotics (Basel) 2021;10:292. [PMID: 33799542 DOI: 10.3390/antibiotics10030292] [Reference Citation Analysis]
188 Amaral MD. How to determine the mechanism of action of CFTR modulator compounds: A gateway to theranostics. Eur J Med Chem 2021;210:112989. [PMID: 33190956 DOI: 10.1016/j.ejmech.2020.112989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
189 Fajac I, Sermet-Gaudelus I. Emerging medicines to improve the basic defect in cystic fibrosis. Expert Opin Emerg Drugs 2022. [PMID: 35731915 DOI: 10.1080/14728214.2022.2092612] [Reference Citation Analysis]
190 Allenby MC, Woodruff MA. Biofabrication of personalised anatomical models and tools for the clinic. Journal of Cystic Fibrosis 2019;18:161-2. [DOI: 10.1016/j.jcf.2019.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
191 Varannai O, Gede N, Juhász MF, Szakács Z, Dembrovszky F, Németh D, Hegyi P, Párniczky A. Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis-A Network Meta-Analysis. Antibiotics (Basel) 2021;10:936. [PMID: 34438986 DOI: 10.3390/antibiotics10080936] [Reference Citation Analysis]
192 Walicka-Serzysko K, Postek M, Milczewska J, Sands D. Lung Clearance Index in Children with Cystic Fibrosis during Pulmonary Exacerbation. J Clin Med 2021;10:4884. [PMID: 34768401 DOI: 10.3390/jcm10214884] [Reference Citation Analysis]
193 Dournes G, Walkup LL, Benlala I, Willmering MM, Macey J, Bui S, Laurent F, Woods JC. The Clinical Use of Lung MRI in Cystic Fibrosis: What, Now, How? Chest 2021;159:2205-17. [PMID: 33345950 DOI: 10.1016/j.chest.2020.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Le Pennec D, Baravalle-Einaudi M, Dupont C, Vecellio L, Dubus JC; GRAM (Aerosols and Cystic Fibrosis Workgroup of the French Cystic Fibrosis Society). Cystic fibrosis in the modern therapeutic era: Give the shower a thought! J Cyst Fibros 2019;18:e56-7. [PMID: 30904464 DOI: 10.1016/j.jcf.2019.03.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
195 Drzymała-Czyż S, Krzyżanowska-Jankowska P, Dziedzic K, Lisowska A, Kurek S, Goździk-Spychalska J, Kononets V, Woźniak D, Mądry E, Walkowiak J. Severe Genotype, Pancreatic Insufficiency and Low Dose of Pancreatic Enzymes Associate with Abnormal Serum Sterol Profile in Cystic Fibrosis. Biomolecules 2021;11:313. [PMID: 33669566 DOI: 10.3390/biom11020313] [Reference Citation Analysis]
196 Oliveira EP, Medeiros Junior P. Palliative care in pulmonary medicine. J Bras Pneumol 2020;46:e20190280. [PMID: 32638839 DOI: 10.36416/1806-3756/e20190280] [Reference Citation Analysis]
197 Bienvenu T, Nguyen-Khoa T. Current and future diagnosis of cystic fibrosis: Performance and limitations. Arch Pediatr 2020;27 Suppl 1:eS19-24. [PMID: 32172931 DOI: 10.1016/S0929-693X(20)30046-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
198 Hojsak I, Chourdakis M, Gerasimidis K, Hulst J, Huysentruyt K, Moreno-Villares JM, Joosten K. What are the new guidelines and position papers in pediatric nutrition: A 2015-2020 overview. Clin Nutr ESPEN 2021;43:49-63. [PMID: 34024560 DOI: 10.1016/j.clnesp.2021.03.004] [Reference Citation Analysis]
199 Al Sinani S, Al-Mulaabed S, Al Naamani K, Sultan R. Cystic Fibrosis Liver Disease: Know More. Oman Med J 2019;34:482-9. [PMID: 31745411 DOI: 10.5001/omj.2019.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Ward N, Morrow S, Stiller K, Holland AE. Exercise as a substitute for traditional airway clearance in cystic fibrosis: a systematic review. Thorax 2021;76:763-71. [DOI: 10.1136/thoraxjnl-2020-215836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
201 Bresnick K, Arteaga-Solis E, Millar SJ, Laird G, LeCamus C. Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies. BMJ Open Respir Res 2021;8:e000998. [PMID: 34857524 DOI: 10.1136/bmjresp-2021-000998] [Reference Citation Analysis]
202 Sherman V, Kondratyeva E, Kashirskaya N, Voronkova A, Nikonova V, Zhekaite E, Kutsev S. Newborn Screening for Cystic Fibrosis in Russia: A Catalyst for Improved Care. Int J Neonatal Screen 2020;6:34. [PMID: 33073029 DOI: 10.3390/ijns6020034] [Reference Citation Analysis]
203 Donadio MVF, Campos NE, Vendrusculo FM, Stofella AM, Almeida ACDS, Ziegler B, Schivinski CIS, Santuzzi CH, Sarges EDSNF, Gonçalves FM, Ribeiro MÂGO, Santana NN, de Paiva SB, de Godoy VCWP, Aquino EDS. Respiratory physical therapy techniques recommended for patients with cystic fibrosis treated in specialized centers. Braz J Phys Ther 2020;24:532-8. [PMID: 31810864 DOI: 10.1016/j.bjpt.2019.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
204 Tejada S, Campogiani L, Solé-Lleonart C, Gómez A, Gallego M, Vendrell M, Soriano JB, Rello J. Inhaled antibiotics for treatment of adults with non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. Eur J Intern Med 2021;90:77-88. [PMID: 33947626 DOI: 10.1016/j.ejim.2021.04.009] [Reference Citation Analysis]
205 Simmonds NJ, van der Ent CK, Colombo C, Kinnman N, Desouza C, Thorat T, Chew ML, Chandarana K, Castellani C. VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non–G551D-CFTR gating mutations. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.05.007] [Reference Citation Analysis]
206 Hatziagorou E, Orenti A, Drevinek P, Kashirskaya N, Mei-zahav M, De Boeck K, Pfleger A, Sciensano MT, Lammertyn E, Macek M, Olesen HV, Farge A, Naehrlich L, Ujhelyi R, Fletcher G, Padoan R, Timpare Z, Malakauskas K, Fustik S, Gulmans V, Turcu O, Pereira L, Mosescu S, Rodic M, Kayserova H, Krivec U, Vazquez-cordero C, de Monestrol I, Lindblad A, Jung A, Makukh H, Carr SB, Cosgriff R, Zolin A. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis–data from the European cystic fibrosis society patient registry. Journal of Cystic Fibrosis 2020;19:376-83. [DOI: 10.1016/j.jcf.2019.08.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
207 Çolak Y, Nordestgaard BG, Afzal S. Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population. Eur Respir J 2020;56:2000558. [DOI: 10.1183/13993003.00558-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
208 Schechter MS. Reevaluating approaches to cystic fibrosis pulmonary exacerbations. Pediatr Pulmonol 2018;53:S51-63. [PMID: 29979495 DOI: 10.1002/ppul.24125] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
209 Barry PJ, Taylor-Cousar JL. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges. Curr Opin Pulm Med 2021;27:554-66. [PMID: 34420018 DOI: 10.1097/MCP.0000000000000819] [Reference Citation Analysis]
210 Southern KW, Clancy JP, Ranganathan S. Aerosolized agents for airway clearance in cystic fibrosis. Pediatr Pulmonol 2019;54:858-64. [PMID: 30884217 DOI: 10.1002/ppul.24306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
211 Marmor M, Jonas A, Mirza A, Rad E, Wong H, Aslakson RA, Aslakson R, Ast K, Carroll T, Dzeng E, Harrison KL, Kaye EC, Leblanc TW, Lo SS, Mckenna K, Nageswaran S, Powers J, Rotella J, Ullrich C, Vickey T. Opportunities to Improve Utilization of Palliative Care Among Adults With Cystic Fibrosis: A Systematic Review. Journal of Pain and Symptom Management 2019;58:1100-1112.e1. [DOI: 10.1016/j.jpainsymman.2019.08.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
212 Petrova G, Yaneva N, Hrbková J, Libik M, Savov A, Macek M Jr. Identification of 99% of CFTR gene mutations in Bulgarian-, Bulgarian Turk-, and Roma cystic fibrosis patients. Mol Genet Genomic Med 2019;7:e696. [PMID: 31245908 DOI: 10.1002/mgg3.696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
213 Volpi S, Carnovale V, Colombo C, Raia V, Blasi F, Pappagallo G; PULMOCARE TEAM. Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.604] [Reference Citation Analysis]
214 Melendo S, Fernández-Polo A, Castellnou Asens I, Mendoza-Palomar N, Barnés-Mayolas M, Soler-Palacín P; Grupo PROA-NEN., Miembros del Grupo PROA-NEN. Prescription quality of prolonged antibiotherapy in pediatrics. Impact of ASP program interventions. Enferm Infecc Microbiol Clin (Engl Ed) 2021;39:134-8. [PMID: 32229130 DOI: 10.1016/j.eimc.2020.02.015] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
215 Victoria CB, Casilda O, Nuria P, José AF, María GO, José SF, Victoria GM, Ignacio RG, Gabriel O. Oral Nutritional Supplements in Adults with Cystic Fibrosis: Effects on Intake, Levels of Fat-Soluble Vitamins, and Bone Remodeling Biomarkers. Nutrients 2021;13:669. [PMID: 33669612 DOI: 10.3390/nu13020669] [Reference Citation Analysis]
216 Mésinèle J, Ruffin M, Guillot L, Boëlle P, Corvol H; on behalf of the French CF Modifier Gene Study Investigators. Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis. JPM 2022;12:252. [DOI: 10.3390/jpm12020252] [Reference Citation Analysis]
217 Ward N, Stiller K, Holland AE. Exercise as a therapeutic intervention for people with cystic fibrosis. Expert Rev Respir Med 2019;13:449-58. [PMID: 30902029 DOI: 10.1080/17476348.2019.1598861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
218 Nayir Buyuksahin H, Emiralioglu N, Ozsezen B, Ademhan Tural D, Sunman B, Guzelkas I, Tezel B, Dayangaç Erden D, Yalçın E, Dogru D, Ozcelik U, Kiper N. Cystic fibrosis newborn screening: Five-year experience from a tertiary care center. Pediatr Pulmonol 2021. [PMID: 34842364 DOI: 10.1002/ppul.25778] [Reference Citation Analysis]
219 Kaplan S, Lee A, Caine N, Charman SC, Bilton D. Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry. J Cyst Fibros 2021;20:324-9. [PMID: 32807645 DOI: 10.1016/j.jcf.2020.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
220 Breuer O, Schultz A, Turkovic L, de Klerk N, Keil AD, Brennan S, Harrison J, Robertson C, Robinson PJ, Sly PD, Ranganathan S, Stick SM, Caudri D. Changing Prevalence of Lower Airway Infections in Young Children with Cystic Fibrosis. Am J Respir Crit Care Med 2019;200:590-9. [PMID: 30811949 DOI: 10.1164/rccm.201810-1919OC] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
221 Malá M, Itterheimová P, Homola L, Vinohradská J, Kubáň P. 3D Printed Skin-Wash Sampler for Sweat Sampling in Cystic Fibrosis Diagnosis Using Capillary Electrophoretic Ion Ratio Analysis. Separations 2021;8:234. [DOI: 10.3390/separations8120234] [Reference Citation Analysis]
222 Zentner D, Celermajer DS, Gentles T, d’Udekem Y, Ayer J, Blue GM, Bridgman C, Burchill L, Cheung M, Cordina R, Culnane E, Davis A, du Plessis K, Eagleson K, Finucane K, Frank B, Greenway S, Grigg L, Hardikar W, Hornung T, Hynson J, Iyengar AJ, James P, Justo R, Kalman J, Kasparian N, Le B, Marshall K, Mathew J, Mcgiffin D, Mcguire M, Monagle P, Moore B, Neilsen J, O’connor B, O’donnell C, Pflaumer A, Rice K, Sholler G, Skinner JR, Sood S, Ward J, Weintraub R, Wilson T, Wilson W, Winlaw D, Wood A. Management of People With a Fontan Circulation: a Cardiac Society of Australia and New Zealand Position statement. Heart, Lung and Circulation 2020;29:5-39. [DOI: 10.1016/j.hlc.2019.09.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
223 Svedberg M, Imberg H, Gustafsson P, Brink M, Caisander H, Lindblad A. Chest X-rays are less sensitive than multiple breath washout examinations when it comes to detecting early cystic fibrosis lung disease. Acta Paediatr 2022;111:1253-60. [PMID: 35181935 DOI: 10.1111/apa.16302] [Reference Citation Analysis]
224 MacFarlane M, Carson L, Crossan A, Bell J, Moore JE, Millar BC. Nebuliser cleaning and disinfection practice in the home among patients with cystic fibrosis. J Infect Prev 2020;21:14-22. [PMID: 32030099 DOI: 10.1177/1757177419855603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
225 Audrézet MP, Munck A. Newborn screening for CF in France: An exemplary national experience. Arch Pediatr 2020;27 Suppl 1:eS35-40. [PMID: 32172935 DOI: 10.1016/S0929-693X(20)30049-X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
226 Mingora CM, Flume PA. Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future. Chest 2021:S0012-3692(21)01127-2. [PMID: 34147501 DOI: 10.1016/j.chest.2021.06.017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
227 De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr 2020;109:893-9. [PMID: 31899933 DOI: 10.1111/apa.15155] [Cited by in Crossref: 71] [Cited by in F6Publishing: 48] [Article Influence: 35.5] [Reference Citation Analysis]
228 Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res 2018;7:F1000 Faculty Rev-921. [PMID: 30002817 DOI: 10.12688/f1000research.14841.1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
229 Zortea A, Benden C, Schmid C, Robinson CA. Gastrografin™ - Induced hyperthyroidism in patients with cystic fibrosis following lung transplantation: A case series. J Cyst Fibros 2019;18:e60-1. [PMID: 31129069 DOI: 10.1016/j.jcf.2019.05.011] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
230 Regard L, Martin C, Chassagnon G, Burgel PR. Acute and chronic non-pulmonary complications in adults with cystic fibrosis. Expert Rev Respir Med 2019;13:23-38. [PMID: 30472915 DOI: 10.1080/17476348.2019.1552832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
231 Wickremasinghe H, Yu HH, Azad MAK, Zhao J, Bergen PJ, Velkov T, Zhou QT, Zhu Y, Li J. Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant Pseudomonas aeruginosa and Minimize Biofilm Formation. Antibiotics (Basel) 2021;10:405. [PMID: 33918040 DOI: 10.3390/antibiotics10040405] [Reference Citation Analysis]
232 Lindenhofer M, Roth L, Mädel C, Götzinger F, Kainz K, Lex C, Frischer T, Reinweber M, Zacharasiewicz A. Wheeze and cough measurements at night in children with respiratory symptoms. BMC Pediatr 2020;20:556. [PMID: 33308199 DOI: 10.1186/s12887-020-02455-5] [Reference Citation Analysis]
233 van der Sar IG, Wijbenga N, Nakshbandi G, Aerts JGJV, Manintveld OC, Wijsenbeek MS, Hellemons ME, Moor CC. The smell of lung disease: a review of the current status of electronic nose technology. Respir Res 2021;22:246. [PMID: 34535144 DOI: 10.1186/s12931-021-01835-4] [Reference Citation Analysis]